These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. ; Chakravarthy U; Harding SP; Rogers CA; Downes SM; Lotery AJ; Wordsworth S; Reeves BC Ophthalmology; 2012 Jul; 119(7):1399-411. PubMed ID: 22578446 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies. Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281 [TBL] [Abstract][Full Text] [Related]
31. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092 [TBL] [Abstract][Full Text] [Related]
32. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial. Mori R; Honda S; Gomi F; Tsujikawa A; Koizumi H; Ochi H; Ohsawa S; Okada AA; Jpn J Ophthalmol; 2023 May; 67(3):301-310. PubMed ID: 37039948 [TBL] [Abstract][Full Text] [Related]
33. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study. Grimaldi G; Cancian G; Rizzato A; Casanova A; Perruchoud-Ader K; Clerici M; Consigli A; Menghini M Graefes Arch Clin Exp Ophthalmol; 2024 Apr; 262(4):1151-1159. PubMed ID: 38047930 [TBL] [Abstract][Full Text] [Related]
34. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P; Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215 [TBL] [Abstract][Full Text] [Related]
35. Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. Schneider M; Bjerager J; Hodzic-Hadzibegovic D; Klefter ON; Subhi Y; Hajari J Graefes Arch Clin Exp Ophthalmol; 2024 Jul; 262(7):2153-2162. PubMed ID: 38416237 [TBL] [Abstract][Full Text] [Related]
36. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom. Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918 [TBL] [Abstract][Full Text] [Related]
39. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477 [TBL] [Abstract][Full Text] [Related]